title: [Colorectal cancer chemotherapy and anti-EGFR therapy].
abstract: Anti-EGFR antibodies show benefits for some K-ras wild-type patients. Addinganti -VEGF monoclonal antibodies to stateof- the-art adjuvant chemotherapy for stage II or III colon cancer does not improve disease-free survival. Bevacizumab shows an additive effect for FOLFOX/FOLFIRI therapy as a first-line chemotherapy. Anti-EGFR therapy has limited adaptation as a first-line chemotherapy based on current evidence and adverse events. When the disease is greatly influenced by tumor regression or has high risk with bevacizumab, anti-EGFR therapy may be used as first-line chemotherapy. Anti-EGFR therapy is recommended as second- or third-line chemotherapy. FOLFIRI therapy is recommended as a second-line therapy and IRI+ Cmab therapy is recommended as a third-line therapy in cases when it is possible to treat usingthree or higher lines. Supportive care is especially important to improve the treatment outcome.
authors.affiliation: Dept. of Medical Oncology, Kochi Health Sciences Center.
authors.forename: Akihito
authors.initials: A
authors.lastname: Tsuji
mesh_terms: D000906:Antibodies / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D066246:ErbB Receptors / Q000276:immunology*; D006801:Humans; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D016879:Salvage Therapy; D018631:ras Proteins / Q000235:genetics
chemical_list: D000906:Antibodies; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins